Vidac Pharma: High‑Leverage Oncology Opportunity Amid Market Shift
Vidac Pharma Holding PLC is poised for high‑leverage growth as it targets metabolic vulnerabilities in oncology, offering a unique upside in a shifting market.
4 minutes to read
Vidac Pharma Holding PLC
Vidac Pharma: Stable Stock, Phase‑2 Cancer Treatment, & Pediatric Oncology Breakthroughs
Vidac Pharma: Investor insights on its €0.78 share price, Phase‑2 VDA‑1102 ointment, pediatric brain‑tumor compassionate use, and future oncology pipeline.
3 minutes to read
Vidac Pharma Showcases VDA‑1102 Compassionate‑Use Success at Eilat Paediatric Cancer Symposium
Vidac Pharma’s VDA‑1102 compassionate‑use case at the Eilat Paediatric Cancer Symposium shows real‑world success for a rare ependymoma, highlighting the company’s rapid‑translation potential in metabolic and dermatologic oncology.
2 minutes to read
Vidac Pharma Announces First Patient Dosed in Phase‑2b Study of VDA‑1102 for High‑Risk Actinic Keratosis
Vidac Pharma’s first patient dose in Phase‑2b VDA‑1102 for high‑risk actinic keratosis marks a pivotal milestone, advancing a promising dermatologic therapy.
2 minutes to read